Last checked at 3 Jan 2024 16:52
LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes
(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades10,231
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,705.00
Bid:
1,701.00
Ask:
1,701.50
Change:
32.00 (1.91%)
Spread:
0.50 (0.029%)
Open:
1,685.50
High:
1,718.50
Low:
1,673.00
Prev. Close:
1,673.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GlaxoSmithKline to buy oncology-focused Tesaro for $5.1bn
Mon, 03rd Dec 2018 12:08
(Sharecast News) - GlaxoSmithKline has agreed to buy US-based oncology-focused pharmaceutical group Tesaro Inc for around $5.1bn (£4bn).Under the terms of the deal, which has been unanimously approved by Tesaro's board, shareholders will receive $75 per share in cash, which represents a premium of 110% to the 30-day volume-weighted average price.Glaxo expects the deal - due to complete in the first quarter of next year - to accelerate the build of its pipeline and commercial capability in oncology.Tesaro is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.Hal Barron, chief scientific officer and president of research and development at GSK, said: "Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. We are optimistic that Zejula will demonstrate benefit in patients with ovarian cancer beyond those who are BRCA-positive as front-line treatment."We are also very excited that through this transaction, we will have the opportunity to work with an outstanding Boston-based oncology group with deep clinical development expertise and together we will explore Zejula's efficacy beyond ovarian cancer into multiple tumour types to help many more patients."Zejula's revenues in its current approved indication as second-line maintenance treatment for ovarian cancer were $166m for the nine months ended 30 September 2018.At 1245 GMT, GSK shares were down 4% to 1,557p and Tesaro shares were up a whopping 60% in pre-market trade at $73.78.
More News
3 Jan 2024 12:10
LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data
(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.
Read more3 Jan 2024 11:07
Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'
(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.
Read more3 Jan 2024 09:23
LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more3 Jan 2024 08:58
LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.
Read more3 Jan 2024 07:54
LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data
(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.
Read more29 Dec 2023 13:01
LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023
(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.
Read more20 Dec 2023 13:29
GSK buys rights to Hansoh Pharma antibody-drug conjugate
(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.
Read more19 Dec 2023 15:36
German court quashes CureVac patent after challenge by BioNTech
CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue
*Read more18 Dec 2023 17:21
Energy stocks lift UK's FTSE 100, Vodafone shines
Vodafone jumps as Iliad offers to merge Italian units
*Read more18 Dec 2023 10:07
GSK's dostarlimab trial in endometrial cancer meets primary endpoint
(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.
Read more18 Dec 2023 07:55
LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000
(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.
Read more18 Dec 2023 07:18
GSK sees success in Jemperli endometrial cancer trial
(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.
Read more17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more